Core Insights - Kyntra Bio, formerly known as FibroGen, is actively participating in investor conferences to engage with potential investors and stakeholders [1][2]. Group 1: Investor Conferences - Kyntra Bio will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, from 2:40-3:10 PM ET in a virtual format [1]. - The company will also present at the Leerink Global Healthcare Conference on March 11, 2026, from 2:20-2:50 PM ET in Miami, FL [1]. - Management will be available for one-on-one meetings during these conferences, and interested investors are encouraged to reach out for scheduling [1]. Group 2: Company Overview - Kyntra Bio is focused on developing novel therapies in oncology and rare diseases, with its lead product, Roxadustat (EVRENZO™), approved in multiple countries for treating anemia in chronic kidney disease patients [2]. - The company is evaluating a Phase 3 trial for Roxadustat in treating anemia associated with lower-risk myelodysplastic syndromes in the U.S. [2]. - Kyntra Bio is also developing FG-3246, a first-in-class antibody-drug conjugate targeting CD46, currently in Phase 2 for metastatic castration-resistant prostate cancer, along with FG-3180, a CD46-targeted PET biomarker [2].

On February 17, 2026, Rock Springs Capital Management LP disclosed in an SEC filing that it sold 159,379 shares of Agios Pharmaceuticals (NASDAQ:AGIO) in the fourth quarter, an estimated $5.59 million transaction based on quarterly average pricing. What happened According to its SEC filing dated February 17, 2026, Rock Springs Capital Management sold 159,379 shares of Agios Pharmaceuticals in the fourth quarter. The estimated transaction value was $5.59 million, based on the average closing price for the ...

Core Insights - Sanofi has filed its Form 20-F with the U.S. SEC and its "Document d'Enregistrement Universel" with the French AMF, which includes the Annual Financial Report [1] - These documents contain complete audited financial statements and are available on the company's website as well as the SEC and AMF websites [1] Company Overview - Sanofi is an R&D driven, AI-powered biopharma company focused on improving lives and fostering growth through innovative medicines and vaccines [2] - The company leverages its understanding of the immune system to develop treatments that benefit millions globally, with a commitment to addressing urgent healthcare, environmental, and societal challenges [2] - Sanofi is publicly traded on EURONEXT under the ticker SAN and on NASDAQ under the ticker SNY [2]

Core Viewpoint - A class action lawsuit has been filed against Quantum Biopharma Ltd. for alleged securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of shareholders of Quantum Biopharma Ltd. and is being handled by Pomerantz LLP [1]. - Investors have until February 23, 2026, to request to be appointed as Lead Plaintiff if they purchased Quantum securities during the Class Period [2]. Group 2: Allegations Against Defendants - The complaint alleges that several financial institutions, including CIBC World Markets and RBC Capital Markets, engaged in manipulative trading practices by placing thousands of spoofed sell orders [4]. - These spoofed orders created a false impression of Quantum's stock price declining, leading other investors to sell their shares at artificially low prices [4]. - After driving the stock price down, the defendants purchased shares at these depressed levels to profit from the manipulation [4]. Group 3: Pomerantz LLP Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud [5]. - The firm has a track record of recovering multimillion-dollar damages for class members over its 85-year history [5].

Company Overview - Terns Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative therapies for liver and metabolic diseases, particularly non-alcoholic steatohepatitis (NASH) and obesity [6] - The company has a diversified pipeline of small-molecule drug candidates with differentiated mechanisms and liver-targeted profiles [6] - Terns Pharmaceuticals reported a market capitalization of $4 billion and a net income of -$94.44 million for the trailing twelve months (TTM) [4] Recent Developments - First Turn Management, LLC disclosed a new position in Terns Pharmaceuticals, acquiring 872,049 shares valued at approximately $35.23 million as of February 13, 2026 [1][2] - This new position represents 4.03% of First Turn Management's total reportable U.S. equity holdings of $875.20 million as of December 31, 2025 [7] - Terns Pharmaceuticals shares were priced at $37.79, reflecting a remarkable one-year price change of 826.2%, significantly outperforming the S&P 500 by 814.43 percentage points [7][4] Pipeline and Product Development - Terns Pharmaceuticals is advancing several drug candidates, including TERN-101 (Phase IIa), TERN-201 (Phase Ib), TERN-501 (Phase I), and TERN-601 (preclinical/early clinical) [8] - The company aims to generate value through the advancement of proprietary drug candidates toward regulatory approval and potential out-licensing or commercialization partnerships [8] Market Performance and Investor Sentiment - The stock's significant price increase was largely driven by positive Phase 1 results for TERN-701 in relapsed and refractory chronic myeloid leukemia (CML), which reported a 75% cumulative major molecular response rate by 24 weeks [9] - The timing of First Turn Management's acquisition is unclear, as it is uncertain whether the shares were purchased before or after the stock's surge following the November data release [10]

Year End Results © Genmab 2024 Forward looking statement This presentation contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and object ...

Core Viewpoint - Cytokinetics (CYTK) is anticipated to report a year-over-year decline in earnings due to lower revenues, with a consensus outlook indicating a quarterly loss of $1.48 per share, representing a 17.5% decrease from the previous year, and revenues expected to be $3.89 million, down 77% from the same quarter last year [1][3]. Earnings Expectations - The upcoming earnings report is scheduled for February 24, and the stock may rise if the reported numbers exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised 1.25% lower in the last 30 days, reflecting a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Cytokinetics is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.95%, suggesting a bearish outlook from analysts [11]. - The stock currently holds a Zacks Rank of 3, making it challenging to predict a beat on the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Cytokinetics was expected to post a loss of $1.59 per share but actually reported a loss of -$1.54, resulting in a positive surprise of +3.14% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [13]. Conclusion - While Cytokinetics does not appear to be a strong candidate for an earnings beat, investors should consider other factors when making decisions regarding the stock ahead of the earnings release [16].

Group 1: Clinical Trial Results - The Phase 1 study results for RLYB116 demonstrated complete and sustained inhibition of terminal complement at a 300 mg dose, with a safety profile consistent with other subcutaneous biologics [2] - RLYB116 showed promising pharmacokinetic and pharmacodynamic results, indicating clinically effective blockade of terminal complement [2] - RLYB116 administered at 150 mg and 300 mg once a week was well tolerated, with no gastrointestinal side effects reported among participants [3] Group 2: Future Plans - Rallybio plans to initiate a Phase 2 clinical trial for immune platelet transfusion refractoriness in the second half of 2026, with topline data expected in 2027 [4] Group 3: Technical Analysis - Rallybio is currently trading 4.5% below its 20-day simple moving average (SMA) and 8.2% below its 100-day SMA, indicating bearish momentum in the short to medium term [5] - Shares have decreased 17.97% over the past 12 months and are positioned closer to their 52-week lows than highs [5] - The combination of neutral RSI and bearish MACD indicates mixed momentum for Rallybio, reflecting uncertainty in the stock's near-term direction [6] Group 4: Sector Performance - Rallybio is part of the healthcare sector, which is currently ranked 5 out of 11 sectors, reflecting mid-tier performance [7] - The healthcare sector has seen a modest increase of 1.46% over the past 30 days and a rise of 3.51% over the last 90 days, highlighting that Rallybio's recent performance has not mirrored this trend [7] Group 5: Market Position - According to Benzinga Edge, Rallybio's momentum is weak, with a score of 17.09, indicating underperformance compared to the broader market [8] - Rallybio shares were down 6.64% at $4.50 at the time of publication [8] - Key resistance for the stock is at $5.50, while key support is at $4.50 [9]

Core Viewpoint - The Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the efficacy of their drug setrusumab during clinical trials [1][3]. Company Overview - Ultragenyx is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases [2]. Allegations of the Lawsuit - The lawsuit claims that Ultragenyx misrepresented the reliability of information regarding the effects of setrusumab on Osteogenesis Imperfecta (OI) patients and downplayed the risks associated with the Phase III Orbit study [3]. - It is alleged that Ultragenyx's optimism regarding the Phase III Orbit study's results was unfounded, as the company did not adequately disclose the risks of relying on Phase II results that lacked a placebo control [3]. Impact of Study Results - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, leading to a stock price drop of over 25% [4]. - Following a December 29, 2025 announcement that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, Ultragenyx's stock fell more than 42% [5]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Ultragenyx common stock during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone, and a total of $8.4 billion over the past five years [7].

Core Insights - GRI Bio, Inc. is advancing a pipeline of Natural Killer T (NKT) cell modulators aimed at treating inflammatory, fibrotic, and autoimmune diseases [1][3] - The company recently reported positive Phase 2a data in Idiopathic Pulmonary Fibrosis (IPF), highlighting significant biomarker improvements related to fibrosis and lung repair [2] Company Overview - GRI Bio is a clinical-stage biopharmaceutical company focused on transforming the treatment landscape for inflammatory, fibrotic, and autoimmune diseases [3] - The company's therapies target NKT cells, which are crucial in regulating the inflammatory response and disease progression [3] - GRI Bio's lead program, GRI-0621, is an RARβγ agonist designed to inhibit iNKT cell activity and is being developed as an oral treatment for IPF, addressing a significant unmet medical need [3] - The company is also developing a pipeline of novel type 2 diverse NKT (dNKT) agonists for systemic lupus erythematosus and has a library of over 500 proprietary compounds to support its growing pipeline [3]